IDH2 R140Q in AITL — much less common than R172 in T-cell lymphoma (myeloid pattern). Ena...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-IDH2-R140Q-AITL |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-AITL |
| Sources | SRC-CIVIC SRC-ESMO-PTCL-2024 |
Actionability Facts
| Biomarker | BIO-IDH-MUTATION |
|---|---|
| Variant | IDH2 R140Q |
| Disease | DIS-AITL |
| ESCAT tier | IIIB |
| Recommended combinations | enasidenib (off-label, exploratory) |
| Evidence summary | IDH2 R140Q in AITL — much less common than R172 in T-cell lymphoma (myeloid pattern). Enasidenib rationale extrapolated; case-report level. |
Notes
ESCAT IIIB. R172 dominant in AITL.
Used By
No reverse references found in the YAML corpus.